A similar application has also been submitted to the EMA to expand the use of Prezcobix to treat HIV-infected children aged 6 years and older.
Johnson & Johnson Submits Supplemental New Drug Application to Expand Use of HIV-1 Treatment Prescovix in Children Ages 6 and Older
Leave a comment
